Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.25
BAX's Cash to Debt is ranked lower than
81% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.42 vs. BAX: 0.25 )
Ranked among companies with meaningful Cash to Debt only.
BAX' s 10-Year Cash to Debt Range
Min: 0.09  Med: 0.25 Max: 0.92
Current: 0.25
0.09
0.92
Equity to Asset 0.29
BAX's Equity to Asset is ranked lower than
86% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. BAX: 0.29 )
Ranked among companies with meaningful Equity to Asset only.
BAX' s 10-Year Equity to Asset Range
Min: 0.22  Med: 0.34 Max: 0.47
Current: 0.29
0.22
0.47
Interest Coverage 16.21
BAX's Interest Coverage is ranked lower than
63% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.79 vs. BAX: 16.21 )
Ranked among companies with meaningful Interest Coverage only.
BAX' s 10-Year Interest Coverage Range
Min: 3.8  Med: 15.34 Max: 32.02
Current: 16.21
3.8
32.02
F-Score: 5
Z-Score: 3.27
M-Score: -2.65
WACC vs ROIC
4.89%
14.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 15.91
BAX's Operating margin (%) is ranked higher than
79% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. BAX: 15.91 )
Ranked among companies with meaningful Operating margin (%) only.
BAX' s 10-Year Operating margin (%) Range
Min: 9.41  Med: 17.31 Max: 22.9
Current: 15.91
9.41
22.9
Net-margin (%) 14.20
BAX's Net-margin (%) is ranked higher than
82% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.95 vs. BAX: 14.20 )
Ranked among companies with meaningful Net-margin (%) only.
BAX' s 10-Year Net-margin (%) Range
Min: 4.08  Med: 12.40 Max: 17.55
Current: 14.2
4.08
17.55
ROE (%) 28.83
BAX's ROE (%) is ranked higher than
94% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.63 vs. BAX: 28.83 )
Ranked among companies with meaningful ROE (%) only.
BAX' s 10-Year ROE (%) Range
Min: 11.12  Med: 25.76 Max: 34.4
Current: 28.83
11.12
34.4
ROA (%) 9.32
BAX's ROA (%) is ranked higher than
79% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.88 vs. BAX: 9.32 )
Ranked among companies with meaningful ROA (%) only.
BAX' s 10-Year ROA (%) Range
Min: 2.79  Med: 8.15 Max: 13.46
Current: 9.32
2.79
13.46
ROC (Joel Greenblatt) (%) 22.04
BAX's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. BAX: 22.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.85  Med: 32.90 Max: 89.4
Current: 22.04
9.85
89.4
Revenue Growth (3Y)(%) 7.90
BAX's Revenue Growth (3Y)(%) is ranked higher than
67% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. BAX: 7.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.5  Med: 7.60 Max: 17.3
Current: 7.9
-3.5
17.3
EBITDA Growth (3Y)(%) 1.90
BAX's EBITDA Growth (3Y)(%) is ranked lower than
63% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. BAX: 1.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -12.2  Med: 7.00 Max: 33
Current: 1.9
-12.2
33
EPS Growth (3Y)(%) -2.80
BAX's EPS Growth (3Y)(%) is ranked lower than
67% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. BAX: -2.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -17.1  Med: 7.60 Max: 61.5
Current: -2.8
-17.1
61.5
» BAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BAX Guru Trades in Q2 2014

John Keeley 37,150 sh (New)
First Eagle Investment 1,000,696 sh (+90872.40%)
Paul Tudor Jones 15,503 sh (+142.23%)
Murray Stahl 9,722 sh (+127.57%)
Jim Simons 1,184,600 sh (+45.81%)
Mario Gabelli 243,400 sh (+7.94%)
Charles Brandes 209,907 sh (+2.61%)
John Buckingham 101,227 sh (+1.10%)
Manning & Napier Advisors, Inc 218,691 sh (+1.06%)
Bill Frels 2,342,897 sh (+0.03%)
Bill Nygren 1,623,000 sh (unchged)
John Rogers 61,251 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
David Dreman Sold Out
Vanguard Health Care Fund Sold Out
Tweedy Browne 2,592,155 sh (-0.37%)
Dodge & Cox 3,382 sh (-0.65%)
Jeff Auxier 25,331 sh (-2.50%)
Jeremy Grantham 3,397,750 sh (-3.51%)
Diamond Hill Capital 1,635,153 sh (-7.58%)
Robert Olstein 60,000 sh (-11.76%)
Scott Black 123,976 sh (-30.98%)
John Hussman 3,725 sh (-50.00%)
Ray Dalio 5,763 sh (-90.74%)
» More
Q3 2014

BAX Guru Trades in Q3 2014

David Dreman 3,397 sh (New)
Ray Dalio 18,463 sh (+220.37%)
John Keeley 40,650 sh (+9.42%)
Charles Brandes 225,023 sh (+7.20%)
John Rogers 63,051 sh (+2.94%)
Diamond Hill Capital 1,676,366 sh (+2.52%)
Manning & Napier Advisors, Inc 222,126 sh (+1.57%)
John Buckingham 101,959 sh (+0.72%)
Scott Black 124,346 sh (+0.30%)
Dodge & Cox 3,382 sh (unchged)
Bill Nygren 1,623,000 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
John Hussman 3,725 sh (unchged)
Murray Stahl 9,722 sh (unchged)
Robert Olstein Sold Out
Bill Frels 2,336,628 sh (-0.27%)
First Eagle Investment 997,056 sh (-0.36%)
Jeff Auxier 25,231 sh (-0.39%)
Tweedy Browne 2,581,277 sh (-0.42%)
Jeremy Grantham 3,253,150 sh (-4.26%)
Mario Gabelli 224,940 sh (-7.58%)
Paul Tudor Jones 9,539 sh (-38.47%)
Jim Simons 649,700 sh (-45.15%)
Signature Select Canadian Fund 51,200 sh (-50.58%)
» More
Q4 2014

BAX Guru Trades in Q4 2014

Joel Greenblatt 5,186 sh (New)
Richard Pzena 3,944,140 sh (New)
Ray Dalio 25,163 sh (+36.29%)
Charles Brandes 238,073 sh (+5.80%)
Murray Stahl 10,272 sh (+5.66%)
Diamond Hill Capital 1,757,369 sh (+4.83%)
Scott Black 130,136 sh (+4.66%)
John Keeley 42,110 sh (+3.59%)
David Dreman 3,504 sh (+3.15%)
Paul Tudor Jones 9,755 sh (+2.26%)
John Buckingham 102,548 sh (+0.58%)
Dodge & Cox 3,382 sh (unchged)
John Hussman 3,725 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Bill Nygren Sold Out
John Rogers 62,951 sh (-0.16%)
Tweedy Browne 2,572,339 sh (-0.35%)
Jeff Auxier 25,131 sh (-0.40%)
Bill Frels 2,326,203 sh (-0.45%)
Manning & Napier Advisors, Inc 181,630 sh (-18.23%)
Mario Gabelli 172,900 sh (-23.14%)
Jeremy Grantham 2,240,590 sh (-31.13%)
First Eagle Investment 676,637 sh (-32.14%)
Jim Simons 176,000 sh (-72.91%)
» More
Q1 2015

BAX Guru Trades in Q1 2015

Joel Greenblatt 244,934 sh (+4622.98%)
Jim Simons 1,946,500 sh (+1005.97%)
Paul Tudor Jones 53,009 sh (+443.40%)
David Dreman 7,876 sh (+124.77%)
Richard Pzena 5,028,418 sh (+27.49%)
John Keeley 53,460 sh (+26.95%)
Manning & Napier Advisors, Inc 188,786 sh (+3.94%)
Scott Black 134,922 sh (+3.68%)
Signature Select Canadian Fund 52,200 sh (+1.95%)
Murray Stahl 10,372 sh (+0.97%)
John Buckingham 102,996 sh (+0.44%)
Bill Frels 2,335,756 sh (+0.41%)
John Hussman 3,725 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
John Rogers 62,951 sh (unchged)
Dodge & Cox 3,382 sh (unchged)
Ray Dalio Sold Out
Diamond Hill Capital 1,754,421 sh (-0.17%)
Tweedy Browne 2,564,814 sh (-0.29%)
Charles Brandes 229,981 sh (-3.40%)
Mario Gabelli 164,850 sh (-4.66%)
Jeff Auxier 5,531 sh (-77.99%)
Jeremy Grantham 423,273 sh (-81.11%)
First Eagle Investment 1,100 sh (-99.84%)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Baxter International Inc

Diamond Hill Capital Comments on Baxter International Inc - Jul 25, 2014

We sold our shares of medical supply manufacturer Baxter International, Inc. (BAX) after we marginally lowered our intrinsic value estimate to reflect an increased likelihood of more meaningful competition for its Hemophilia franchise. This resulted in an insufficient discount to our estimate of intrinsic value, and we exited the position.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Baxter International - Jan 15, 2014

Baxter International, Inc. (BAX), a medical supply manufacturer, declined during the quarter due to concerns that it could lose more market share than expected in the hemophilia market. 

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Baxter International Inc

Richard Pzena's New Buys
Wharton School cum laude and Founder and Co-Chief Investment Officer of Pzena Investment Management LLC Richard Pzena (Trades, Portfolio) believes in investing in good businesses – but only when they go on sale. Read more...
Richard Pzena's 5 New Q4 Stock Buys
Richard Pzena (Trades, Portfolio) of the $27.7 billion Pzena Investment Management purchased five new stocks in the fourth quarter, according to his portfolio update released Friday. Read more...
Diamond Hill Capital Comments on Baxter International Inc
We sold our shares of medical supply manufacturer Baxter International, Inc. (BAX) after we marginally lowered our intrinsic value estimate to reflect an increased likelihood of more meaningful competition for its Hemophilia franchise. This resulted in an insufficient discount to our estimate of intrinsic value, and we exited the position. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 16.30
BAX's P/E(ttm) is ranked higher than
82% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.10 vs. BAX: 16.30 )
Ranked among companies with meaningful P/E(ttm) only.
BAX' s 10-Year P/E(ttm) Range
Min: 12.15  Med: 19.02 Max: 57.43
Current: 16.3
12.15
57.43
Forward P/E 17.45
BAX's Forward P/E is ranked higher than
72% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.98 vs. BAX: 17.45 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.60
BAX's PE(NRI) is ranked higher than
72% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.00 vs. BAX: 20.60 )
Ranked among companies with meaningful PE(NRI) only.
BAX' s 10-Year PE(NRI) Range
Min: 12.11  Med: 19.71 Max: 58.45
Current: 20.6
12.11
58.45
P/B 5.28
BAX's P/B is ranked lower than
75% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. BAX: 5.28 )
Ranked among companies with meaningful P/B only.
BAX' s 10-Year P/B Range
Min: 3.78  Med: 4.93 Max: 6.19
Current: 5.28
3.78
6.19
P/S 2.29
BAX's P/S is ranked higher than
56% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. BAX: 2.29 )
Ranked among companies with meaningful P/S only.
BAX' s 10-Year P/S Range
Min: 1.85  Med: 2.51 Max: 3.88
Current: 2.29
1.85
3.88
PFCF 51.20
BAX's PFCF is ranked lower than
74% of the 81 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.24 vs. BAX: 51.20 )
Ranked among companies with meaningful PFCF only.
BAX' s 10-Year PFCF Range
Min: 12.81  Med: 21.83 Max: 59.68
Current: 51.2
12.81
59.68
POCF 14.03
BAX's POCF is ranked higher than
70% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.89 vs. BAX: 14.03 )
Ranked among companies with meaningful POCF only.
BAX' s 10-Year POCF Range
Min: 8.42  Med: 12.84 Max: 18.82
Current: 14.03
8.42
18.82
EV-to-EBIT 18.38
BAX's EV-to-EBIT is ranked higher than
61% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.04 vs. BAX: 18.38 )
Ranked among companies with meaningful EV-to-EBIT only.
BAX' s 10-Year EV-to-EBIT Range
Min: 10  Med: 15.40 Max: 28.8
Current: 18.38
10
28.8
PEG 3.75
BAX's PEG is ranked lower than
61% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.97 vs. BAX: 3.75 )
Ranked among companies with meaningful PEG only.
BAX' s 10-Year PEG Range
Min: 0.65  Med: 2.20 Max: 1169
Current: 3.75
0.65
1169
Shiller P/E 18.39
BAX's Shiller P/E is ranked higher than
80% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.41 vs. BAX: 18.39 )
Ranked among companies with meaningful Shiller P/E only.
BAX' s 10-Year Shiller P/E Range
Min: 14.63  Med: 23.10 Max: 36.78
Current: 18.39
14.63
36.78
Current Ratio 1.60
BAX's Current Ratio is ranked lower than
74% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.56 vs. BAX: 1.60 )
Ranked among companies with meaningful Current Ratio only.
BAX' s 10-Year Current Ratio Range
Min: 1.08  Med: 1.65 Max: 2.7
Current: 1.6
1.08
2.7
Quick Ratio 1.03
BAX's Quick Ratio is ranked lower than
76% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.68 vs. BAX: 1.03 )
Ranked among companies with meaningful Quick Ratio only.
BAX' s 10-Year Quick Ratio Range
Min: 0.74  Med: 1.10 Max: 2.02
Current: 1.03
0.74
2.02
Days Inventory 156.51
BAX's Days Inventory is ranked lower than
66% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 125.77 vs. BAX: 156.51 )
Ranked among companies with meaningful Days Inventory only.
BAX' s 10-Year Days Inventory Range
Min: 114.03  Med: 137.80 Max: 153.92
Current: 156.51
114.03
153.92
Days Sales Outstanding 56.81
BAX's Days Sales Outstanding is ranked higher than
56% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.15 vs. BAX: 56.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAX' s 10-Year Days Sales Outstanding Range
Min: 58.53  Med: 72.54 Max: 120.69
Current: 56.81
58.53
120.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.94
BAX's Dividend Yield is ranked higher than
87% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. BAX: 2.94 )
Ranked among companies with meaningful Dividend Yield only.
BAX' s 10-Year Dividend Yield Range
Min: 1.13  Med: 1.93 Max: 3.2
Current: 2.94
1.13
3.2
Dividend Payout 0.61
BAX's Dividend Payout is ranked lower than
81% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.34 vs. BAX: 0.61 )
Ranked among companies with meaningful Dividend Payout only.
BAX' s 10-Year Dividend Payout Range
Min: 0.26  Med: 0.43 Max: 3.4
Current: 0.61
0.26
3.4
Dividend growth (3y) 17.50
BAX's Dividend growth (3y) is ranked higher than
73% of the 56 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.90 vs. BAX: 17.50 )
Ranked among companies with meaningful Dividend growth (3y) only.
BAX' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 4.10 Max: 22.5
Current: 17.5
0
22.5
Yield on cost (5-Year) 5.94
BAX's Yield on cost (5-Year) is ranked higher than
96% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.52 vs. BAX: 5.94 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BAX' s 10-Year Yield on cost (5-Year) Range
Min: 2.28  Med: 3.90 Max: 6.46
Current: 5.94
2.28
6.46
Share Buyback Rate 1.50
BAX's Share Buyback Rate is ranked higher than
87% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.10 vs. BAX: 1.50 )
Ranked among companies with meaningful Share Buyback Rate only.
BAX' s 10-Year Share Buyback Rate Range
Min: 7.7  Med: 0.80 Max: -10.6
Current: 1.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 25.60
BAX's Price/Tangible Book is ranked lower than
93% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.32 vs. BAX: 25.60 )
Ranked among companies with meaningful Price/Tangible Book only.
BAX' s 10-Year Price/Tangible Book Range
Min: 3.89  Med: 10.15 Max: 27.72
Current: 25.6
3.89
27.72
Price/Projected FCF 1.51
BAX's Price/Projected FCF is ranked higher than
59% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.77 vs. BAX: 1.51 )
Ranked among companies with meaningful Price/Projected FCF only.
BAX' s 10-Year Price/Projected FCF Range
Min: 1.1  Med: 2.21 Max: 4.96
Current: 1.51
1.1
4.96
Price/DCF (Earnings Based) 1.05
BAX's Price/DCF (Earnings Based) is ranked higher than
83% of the 18 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.72 vs. BAX: 1.05 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.92
BAX's Price/Median PS Value is ranked higher than
71% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.24 vs. BAX: 0.92 )
Ranked among companies with meaningful Price/Median PS Value only.
BAX' s 10-Year Price/Median PS Value Range
Min: 0.38  Med: 1.04 Max: 2.55
Current: 0.92
0.38
2.55
Price/Peter Lynch Fair Value 3.09
BAX's Price/Peter Lynch Fair Value is ranked lower than
80% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.96 vs. BAX: 3.09 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.73  Med: 2.50 Max: 8.11
Current: 3.09
0.73
8.11
Price/Graham Number 4.78
BAX's Price/Graham Number is ranked lower than
76% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.51 vs. BAX: 4.78 )
Ranked among companies with meaningful Price/Graham Number only.
BAX' s 10-Year Price/Graham Number Range
Min: 1.91  Med: 3.25 Max: 6.68
Current: 4.78
1.91
6.68
Earnings Yield (Greenblatt) (%) 5.47
BAX's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. BAX: 5.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BAX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.5  Med: 6.50 Max: 10
Current: 5.47
3.5
10
Forward Rate of Return (Yacktman) (%) 10.68
BAX's Forward Rate of Return (Yacktman) (%) is ranked higher than
50% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.68 vs. BAX: 10.68 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BAX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 1.3  Med: 11.70 Max: 25.5
Current: 10.68
1.3
25.5

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, COV, TMO, COO, ISRG » details
Traded in other countries:BTL.Germany, BAX.Mexico, BAX.Switzerland, 0QK8.UK,
Baxter International Inc was incorporated in Delaware in 1931. The Company is a healthcare company. It is engaged in the development, manufacture and sale of products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company applies a combination of medical devices, pharmaceuticals and biotechnology to create products that advance patient care. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The Company operates in two segments namely BioScience and Medical Products. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as bio surgery products; and vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics, as well as products and services related to pharmacy compounding, drug formulation and packaging technologies. The business manufactures solutions and other products for peritoneal dialysis, a home-based therapy, and also distributes products for hemodialysis, which is generally conducted in a hospital or clinic. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. The BioScience segment faces competitors from pharmaceutical, biotechnology and other companies. The Medical Products segment faces competition from medical device manufacturers and pharmaceutical companies. The Company's operations and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.
» More Articles for BAX

Headlines

Articles On GuruFocus.com
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Live Off Your Monthly Dividend Portfolio Mar 19 2015 
Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
Best Stock Pick For Long Term Investors Feb 10 2015 
Richard Pzena's New Buys Feb 09 2015 
Richard Pzena's 5 New Q4 Stock Buys Feb 06 2015 
Expectations, Price, and Fundamentals (Or Congressional Questions Gone Awry) Jan 23 2015 
Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 

More From Other Websites
Baxter's MAA for MM-398 Accepted in International Markets - Analyst Blog Jun 29 2015
Baxter Shares Bid Up Ahead Of Spinoff Jun 25 2015
Baxter Provides Update on BAX 335 Trial Ahead of Spin-Off - Analyst Blog Jun 25 2015
MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the... Jun 25 2015
Jim Cramer: Baxter International (BAX) Stock Has 'Real Value' Jun 25 2015
U.S. FDA Grants Priority Review for MM-398 New Drug Application Jun 25 2015
U.S. FDA Grants Priority Review for MM-398 New Drug Application Jun 25 2015
Jim Cramer's Top Takeaways: Baxter International, Mondelez, Netflix Jun 25 2015
Jim Cramer's 'Mad Money' Recap: Take the Market Drop in Stride Jun 24 2015
Cramer: Icahn has to shift his focus Jun 24 2015
Baxter Int'l. (BAX) Stock Gains on Trial Update Ahead of Drug Division Spin Off Jun 24 2015
With spinout planned for next week, Baxalta provides hemophilia update Jun 24 2015
Why traders are hedging Baxter Jun 24 2015
Baxalta Reports Continued Progress on Phase 1/2 Clinical Trial of BAX335, Investigational Gene... Jun 24 2015
Coverage initiated on Baxter by Goldman Jun 24 2015
BAXTER INTERNATIONAL INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Jun 23 2015
Early movers: CI, WMB, PFE, ALL, AAPL & more Jun 22 2015
Baxalta to replace QEP Resources Inc. in S&P 500 index Jun 19 2015
Baxalta to replace QEP Resources Inc. in S&P 500 index Jun 19 2015
The Priceline Group Set to Join the S&P 100; Baxalta to Join the 500; Other Changes to S&P MidCap... Jun 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK